Tirzepatide vs Retatrutide: Research Compounds Compared

Tirzepatide and Retatrutide are incretin-receptor agonists studied in metabolic research. The key structural difference is how many receptors they target: tirzepatide is a dual agonist, retatrutide a triple agonist. Material sold here is research-use-only — not for human use.

• Tirzepatide: dual agonist — GLP-1 and GIP receptors.
• Retatrutide: triple agonist — GLP-1, GIP and glucagon receptors.
• Approval: tirzepatide is an FDA-approved medication; retatrutide is investigational.
• Status: research-grade material is for laboratory use only.

The core difference: receptor targets

Both molecules belong to the incretin class, which acts on hormone receptors involved in metabolic regulation. The distinction is the number of receptors engaged: adding glucagon-receptor activity is what separates the triple agonist (retatrutide) from the dual agonist (tirzepatide), and it is the main focus of comparative research.

Why the extra receptor is studied

In preclinical models, glucagon-receptor activity is associated with effects on energy expenditure and hepatic fat metabolism — which is why the triple-agonist design is of research interest beyond the dual-agonist approach. Comparative work examines how the added pathway changes the overall metabolic profile in models.

• Tirzepatide — GLP-1 + GIP; an established, approved dual agonist.
• Retatrutide — adds glucagon-receptor agonism; still investigational.

Related products

Explore the individual research compounds: Tirzepatide and Retatrutide. New to the category? See What Are Research Peptides?

Research status

Tirzepatide is an FDA-approved prescription medication for specific medical conditions; retatrutide is investigational and not approved. Material sold here is research-grade and intended only for laboratory research — not for human use. Nothing here is a health claim or recommendation for use.